Cargando…

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation

Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of bevacizumab, the development of GI ulcers has not been reported. We identified 18 patients with ACC who participated in a pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Tol, J., Cats, A., Mol, L., Koopman, M., Bos, M. M. E. M., van der Hoeven, J. J. M., Antonini, N. F., van Krieken, J. H. J. M., Punt, C. J. A.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480515/
https://www.ncbi.nlm.nih.gov/pubmed/18335169
http://dx.doi.org/10.1007/s10637-008-9125-4
_version_ 1782157954886139904
author Tol, J.
Cats, A.
Mol, L.
Koopman, M.
Bos, M. M. E. M.
van der Hoeven, J. J. M.
Antonini, N. F.
van Krieken, J. H. J. M.
Punt, C. J. A.
author_facet Tol, J.
Cats, A.
Mol, L.
Koopman, M.
Bos, M. M. E. M.
van der Hoeven, J. J. M.
Antonini, N. F.
van Krieken, J. H. J. M.
Punt, C. J. A.
author_sort Tol, J.
collection PubMed
description Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of bevacizumab, the development of GI ulcers has not been reported. We identified 18 patients with ACC who participated in a phase III multicentre trial which included chemotherapy and bevacizumab, who developed a GI ulcer (n = 6), perforation (n = 8) or both (n = 4). The risk of developing a symptomatic GI ulcer or perforation was 1.3% and 1.6%, respectively. Central review of the histology specimens showed ulceration and/or granulation tissue with neovascularisation. The majority (89%) of events developed early during treatment. Given these observations, as well as the relationship between VEGF and mucosal injury healing, we suggest that GI ulcers may occur as a side effect of treatment with bevacizumab and may herald perforation.
format Text
id pubmed-2480515
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-24805152008-07-22 Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation Tol, J. Cats, A. Mol, L. Koopman, M. Bos, M. M. E. M. van der Hoeven, J. J. M. Antonini, N. F. van Krieken, J. H. J. M. Punt, C. J. A. Invest New Drugs Phase III Studies Chemotherapy plus bevacizumab is currently considered as the standard 1st line treatment of advanced colorectal cancer (ACC). Whereas GI perforation is a known side effect of bevacizumab, the development of GI ulcers has not been reported. We identified 18 patients with ACC who participated in a phase III multicentre trial which included chemotherapy and bevacizumab, who developed a GI ulcer (n = 6), perforation (n = 8) or both (n = 4). The risk of developing a symptomatic GI ulcer or perforation was 1.3% and 1.6%, respectively. Central review of the histology specimens showed ulceration and/or granulation tissue with neovascularisation. The majority (89%) of events developed early during treatment. Given these observations, as well as the relationship between VEGF and mucosal injury healing, we suggest that GI ulcers may occur as a side effect of treatment with bevacizumab and may herald perforation. Springer US 2008-03-12 2008 /pmc/articles/PMC2480515/ /pubmed/18335169 http://dx.doi.org/10.1007/s10637-008-9125-4 Text en © The Author(s) 2008 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Phase III Studies
Tol, J.
Cats, A.
Mol, L.
Koopman, M.
Bos, M. M. E. M.
van der Hoeven, J. J. M.
Antonini, N. F.
van Krieken, J. H. J. M.
Punt, C. J. A.
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
title Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
title_full Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
title_fullStr Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
title_full_unstemmed Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
title_short Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
title_sort gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation
topic Phase III Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480515/
https://www.ncbi.nlm.nih.gov/pubmed/18335169
http://dx.doi.org/10.1007/s10637-008-9125-4
work_keys_str_mv AT tolj gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation
AT catsa gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation
AT moll gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation
AT koopmanm gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation
AT bosmmem gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation
AT vanderhoevenjjm gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation
AT antonininf gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation
AT vankriekenjhjm gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation
AT puntcja gastrointestinalulcerationasapossiblesideeffectofbevacizumabwhichmayheraldperforation